Ipsen

Alumis provides precision medicines. They transform the lives of patients with autoimmune diseases. They bring a proven track record in precision drug development of groundbreaking therapies. They rewrite the autoimmune treatment playbook with a unique precision analytics platform to advancing their understanding of immunologic diseases. They build a pipeline of therapeutics based on genetically validated targets for application in the treatment of multiple autoimmune disease indications.

AbbVie in Campbell is a pharmaceutical company dedicated to discovering and developing innovative medicines for the future. Their mission is to improve the quality of life for individuals by providing effective healthcare solutions that enhance well-being. Generated from their website's infomation

Pionyr Immunotherapeutics, Inc., a biotechnology company based in South San Francisco, CA, was acquired by Ikena Oncology, Inc. in August 2023. Their innovative Myeloid Tuning programs aim to enhance the immune system's anti-tumor response by modifying the cellular infiltrate of the tumor microenvironment. With clinical programs targeting TREM2 and TREM1, Pionyr focuses on selectively depleting and reprogramming tumor-associated macrophages responsible for immunosuppression, demonstrating safety in Phase 1a b trials alone and in combination with pembrolizumab. Additionally, their IND-ready program, PY265 anti-MARCO, aims to activate the immune system in the tumor microenvironment. Pionyr Immunotherapeutics has made significant contributions to the field of immunotherapy, as evidenced by their posters, publications, and whitepapers. As part of Ikena Oncology, the company's business development team is open to discussions regarding licensing and partnerships for their pioneering programs. With a commitment to advancing cancer treatment, Pionyr Immunotherapeutics continues to make strides in developing novel therapies to combat tumors and improve patient outcomes.Generated from the website